Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In conversation with Xin Lu

Ludwig Oxford Director Professor Xin Lu features in this edition of the FEBS Journal.

Vacancy: Postdoctoral Researcher in Methyltransferases


Grade 7: Salary in range £32,817 - £40,322 per annum

Ludwig Oxford alumni’s biotech success

Scenic Biotech, co-founded by former Ludwig Oxford group leader Sebastian Nijman, collaborates with Roche group member Genentech in a $375m deal.

$410 million buy out for Ludwig Oxford cancer detection technology

Oxford spin-out Base Genomics is acquired by early cancer detection company Exact Sciences.

CRUK Oxford Centre Symposium 2020

Two Ludwig Oxford group leaders present their work at this year’s virtual gathering of the Oxford cancer community.

Probing proteasomal subtypes

Professor Benoit Van den Eynde’s lab compares the abilities of four proteasome subtypes to degrade ubiquitinated or oxidised proteins.

NDM prize studentships - apply now

Ludwig Oxford is currently recruiting exceptional students for fully funded four-year NDM prize DPhil studentships commencing in October 2021.

DPhil in Cancer Science Programme - apply now

The University of Oxford is recruiting its second intake to study for a DPhil in Cancer Science commencing in October 2021.

Chunxiao Song: The chemical biologist

Ludwig Oxford’s Dr Chunxiao Song is featured in Ludwig Cancer Research’s Annual Research Highlights Report.

Investigating mechanisms of gene repression

Skirmantas Kriaucionis’ lab teases apart the contributions of different mechanisms to repress gene expression.

Investigating the role of Salmonella toxin in gall bladder cancer

An innovative gall bladder organoid model provides mechanistic insights into the link between Salmonella Paratyphi A infection and gall bladder cancer.

Insights into mTORC1 regulation

Using quantitative genetic screens, researchers from Professor Sebastian Nijman’s lab learn more about the regulation of a key growth control pathway.

Collaboration with Magdalen College outreach to run remote work experience

Public Engagement

Ludwig Oxford's Dr Tammie Bishop organised a week of work experience for fifteen year 12 students in collaboration with the Magdalen Outreach Team.

Using machine-learning approaches to identify blood cancer types

Improving the accuracy of myeloproliferative neoplasm typing at diagnosis will enable better selection of treatments for improved patient outcomes.

Targeting the aryl hydrocarbon receptor

Dr Pedro Moura Alves secures funding to screen for drugs that regulate aryl hydrocarbon receptor (AHR) activity.

Funding success for Ludwig Oxford early career researchers

Drs Michael McClellan, Marketa Tomkova and Yurena Vivas-Garcia win CRUK Oxford Centre Development Fund awards to pump-prime their research.

Uncovering roles for ubiquitin ligases

Mapping the protein-protein interactions of ubiquitin ligases in the endoplasmic reticulum has revealed a new complex that modulates innate immune signalling.

Linking cancer risk and anthropometric traits

Heritable variants in common cancer genes link anthropometric features like height with cancer risk.

Ludwig Oxford welcomes cancer epigenetics researcher Yang Shi

Yang Shi has been appointed a Member of the Ludwig Oxford Branch to continue his research into chromatin, RNA modifications and cancer.

Insights into the two faces of AMPK, a key nutrient sensor

Professor Colin Goding and colleagues reveal that a distinct metabolic environment in colon cancer cells allows AMPK to be activated by glucose to drive cancer proliferation, with implications for AMPK-targeting cancer drugs.

Load More